SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formu-
lation

SECTION 1: Identification of the substance/mixture and of the company/undertaking

1.1 Product identifier
   Trade name : Gentamicin / Betamethasone Ointment Formulation

1.2 Relevant identified uses of the substance or mixture and uses advised against
   Use of the Sub-
   stance/Mixture : Pharmaceutical

1.3 Details of the supplier of the safety data sheet
   Company : MSD
   Shotton Lane
   NE23 3JU Cramlington NU - Great Britain
   Telephone : 44 1 670 59 30 00
   Telefax : 908-735-1496
   E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

1.4 Emergency telephone number
   1-908-423-6000

SECTION 2: Hazards identification

2.1 Classification of the substance or mixture

Classification (REGULATION (EC) No 1272/2008)
- Reproductive toxicity, Category 1B: H360D: May damage the unborn child.
- Specific target organ toxicity - repeated exposure, Category 1: H372: Causes damage to organs through pro-
longed or repeated exposure.
- Long-term (chronic) aquatic hazard, Category 1: H410: Very toxic to aquatic life with long lasting effects.

2.2 Label elements

Labelling (REGULATION (EC) No 1272/2008)
- Hazard pictograms
- Signal word : Danger
- Hazard statements : H360D May damage the unborn child.
                      H372 Causes damage to organs through prolonged or repeated exposure.
                      H410 Very toxic to aquatic life with long lasting effects.
Precautionary statements:

**Prevention:**
- P201 Obtain special instructions before use.
- P264 Wash skin thoroughly after handling.
- P273 Avoid release to the environment.
- P280 Wear protective gloves/protective clothing/eye protection/face protection.

**Response:**
- P308 + P313 IF exposed or concerned: Get medical advice/attention.
- P391 Collect spillage.

Hazardous components which must be listed on the label:
- betamethasone

### 2.3 Other hazards
None known.

### SECTION 3: Composition/information on ingredients

#### 3.2 Mixtures

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>EC-No.</th>
<th>Index-No.</th>
<th>Classification</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin oil</td>
<td>8012-95-1</td>
<td>232-384-2</td>
<td></td>
<td>Asp. Tox. 1; H304</td>
<td>5</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>215-765-8</td>
<td></td>
<td>Repr. 1A; H360D STOT RE 1; H372 (Kidney, inner ear) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 100 M-Factor (Chronic aquatic toxicity): 1</td>
<td>0,1</td>
</tr>
<tr>
<td>betamethasone</td>
<td>378-44-9</td>
<td>206-825-4</td>
<td></td>
<td>Acute Tox. 2; H330 Repr. 1B; H360D STOT RE 1; H372 (Pituitary gland, Immune system, muscle, thymus gland, Blood, Ad-</td>
<td>0,064</td>
</tr>
</tbody>
</table>
Gentamicin / Betamethasone Ointment Formulation

SECTION 4: First aid measures

4.1 Description of first aid measures

General advice : In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.

Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).

If inhaled : If inhaled, remove to fresh air. Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.

In case of eye contact : Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.

If swallowed : If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.

4.2 Most important symptoms and effects, both acute and delayed

Risks : May damage the unborn child. Causes damage to organs through prolonged or repeated exposure.

4.3 Indication of any immediate medical attention and special treatment needed

Treatment : Treat symptomatically and supportively.
SECTION 5: Firefighting measures

5.1 Extinguishing media

- Suitable extinguishing media: Water spray, Alcohol-resistant foam, Carbon dioxide (CO2), Dry chemical
- Unsuitable extinguishing media: None known.

5.2 Special hazards arising from the substance or mixture

- Specific hazards during firefighting: Exposure to combustion products may be a hazard to health.
- Hazardous combustion products: Carbon oxides

5.3 Advice for firefighters

- Special protective equipment for firefighters: In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.
- Specific extinguishing methods: Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.

SECTION 6: Accidental release measures

6.1 Personal precautions, protective equipment and emergency procedures

- Personal precautions: Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

6.2 Environmental precautions

- Environmental precautions: Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.

6.3 Methods and material for containment and cleaning up

- Methods for cleaning up: Sweep up or vacuum up spillage and collect in suitable container for disposal. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items...
employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

6.4 Reference to other sections
See sections: 7, 8, 11, 12 and 13.

SECTION 7: Handling and storage

7.1 Precautions for safe handling

Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling : Do not get on skin or clothing.
Do not breathe dust, fume, gas, mist, vapours or spray.
Do not swallow.
Avoid contact with eyes.
Wash skin thoroughly after handling.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Do not eat, drink or smoke when using this product.
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store locked up. Keep tightly closed. Store in accordance with the particular national regulations.

Advice on common storage : Do not store with the following product types:
Strong oxidizing agents
Organic peroxides
Explosives
Gases

7.3 Specific end use(s)
Specific use(s) : No data available
SECTION 8: Exposure controls/personal protection

8.1 Control parameters

### Occupational Exposure Limits

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type (Form of exposure)</th>
<th>Control parameters</th>
<th>Basis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>8009-03-8</td>
<td>TWA (Vapour)</td>
<td>50 mg/m⁢³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist and particles)</td>
<td>1 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>Paraffin oil</td>
<td>8012-95-1</td>
<td>TWA (Vapour)</td>
<td>50 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td></td>
<td></td>
<td>TWA (Mist and particles)</td>
<td>1 mg/m³</td>
<td>FOR-2011-12-06-1358</td>
</tr>
<tr>
<td>Gentamicin</td>
<td>1403-66-3</td>
<td>TWA</td>
<td>0.1 mg/m³ (OEB 2)</td>
<td>Internal</td>
</tr>
<tr>
<td>Betamethasone</td>
<td>378-44-9</td>
<td>TWA</td>
<td>1 µg/m³ (OEB 4)</td>
<td>Internal</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>End Use</th>
<th>Exposure routes</th>
<th>Potential health effects</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paraffin oil</td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term systemic effects</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Short-term exposure</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Long-term local effects</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td></td>
<td>Workers</td>
<td>Inhalation</td>
<td>Acute local effects</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

<table>
<thead>
<tr>
<th>Substance name</th>
<th>Environmental Compartment</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Petrolatum</td>
<td>Oral (Secondary Poisoning)</td>
<td>9.33 mg/kg food</td>
</tr>
</tbody>
</table>

8.2 Exposure controls

### Engineering measures

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., vacuum conveying from a closed system, packout head with inflatable seal from stationary container, ventilated enclosure, etc.).

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies.

### Personal protective equipment

- **Eye protection**: Wear safety glasses with side shields or goggles.
  - If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.
  - Wear a faceshield or other full face protection if there is a
potentially for direct contact to the face with dusts, mists, or aerosols.

Hand protection

Material: Chemical-resistant gloves

Remarks: Consider double gloving.

Skin and body protection

Material: Work uniform or laboratory coat.
Remarks: Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.
Use appropriate degowning techniques to remove potentially contaminated clothing.

Respiratory protection

Material: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Remarks: Equipment should conform to NS EN 14387
Filter type: Combined particulates and organic vapour type (A-P)

SECTION 9: Physical and chemical properties

9.1 Information on basic physical and chemical properties

Appearance: ointment
Colour: No data available
Odour: No data available
Odour Threshold: No data available
pH: No data available
Melting point/freezing point: No data available
Initial boiling point and boiling range: No data available
Flash point: No data available
Evaporation rate: No data available
Flammability (solid, gas): Not classified as a flammability hazard
Upper explosion limit / Upper flammability limit: No data available
Lower explosion limit / Lower flammability limit: No data available
Vapour pressure: No data available
Relative vapour density: No data available
Relative density: No data available
Density: No data available
Gentamicin / Betamethasone Ointment Formulation

SECTION 10: Stability and reactivity

10.1 Reactivity
   Not classified as a reactivity hazard.

10.2 Chemical stability
   Stable under normal conditions.

10.3 Possibility of hazardous reactions
   Hazardous reactions : Can react with strong oxidizing agents.

10.4 Conditions to avoid
   Conditions to avoid : None known.

10.5 Incompatible materials
   Materials to avoid : Oxidizing agents

10.6 Hazardous decomposition products
   No hazardous decomposition products are known.

SECTION 11: Toxicological information

11.1 Information on toxicological effects
   Information on likely routes of exposure : Skin contact, Ingestion
**SAFETY DATA SHEET**

according to Regulation (EC) No. 1907/2006

---

**Gentamicin / Betamethasone Ointment Formulation**

**Version**

4.1

**Revision Date:**

10.10.2020

**SDS Number:**

1842226-00008

**Date of last issue:**

23.03.2020

**Date of first issue:**

19.07.2017

---

**Eye contact**

**Acute toxicity**

Not classified based on available information.

**Components:**

**Paraffin oil:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

Acute dermal toxicity : LD50 (Rabbit): > 2.000 mg/kg

Assessment: The substance or mixture has no acute dermal toxicity

**Gentamicin:**

Acute oral toxicity : LD50 (Rat): 8.000 - 10.000 mg/kg

LD50 (Mouse): 10.000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 0,2 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Remarks: No mortality observed at this dose.

Acute toxicity (other routes of administration) : LD50 (Rat): 67 - 96 mg/kg

Application Route: Intravenous

LD50 (Rat): 371 - 384 mg/kg

Application Route: Intramuscular

LDLo (Monkey): 30 mg/kg

Application Route: Intravenous

**Betamethasone:**

Acute oral toxicity : LD50 (Rat): > 5.000 mg/kg

LD50 (Mouse): > 4.500 mg/kg

Acute inhalation toxicity : LC50 (Rat): 0,4 mg/l

Exposure time: 4 h

---

**Skin corrosion/irritation**

Not classified based on available information.

**Components:**

**Paraffin oil:**

Species : Rabbit

Result : No skin irritation

**Gentamicin:**
# Gentamicin / Betamethasone Ointment Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10.10.2020</td>
<td>1842226-00008</td>
<td>23.03.2020</td>
</tr>
</tbody>
</table>

**Species**: Rabbit  
**Result**: Mild skin irritation

**Species**: Rabbit  
**Result**: Mild skin irritation

### Serious eye damage/eye irritation
Not classified based on available information.

**Components:**

**Paraffin oil:**
- **Species**: Rabbit  
- **Result**: No eye irritation

**Gentamicin:**
- **Species**: Rabbit  
- **Result**: Mild eye irritation

**betamethasone:**
- **Species**: Rabbit  
- **Result**: No eye irritation

**Respiratory or skin sensitisation**

**Skin sensitisation**
Not classified based on available information.

**Respiratory sensitisation**
Not classified based on available information.

**Components:**

**Gentamicin:**
- **Remarks**: No data available

**betamethasone:**
- **Exposure routes**: Dermal  
- **Species**: Guinea pig  
- **Result**: Weak sensitizer

**Germ cell mutagenicity**
Not classified based on available information.

**Components:**

**Gentamicin:**
- **Genotoxicity in vitro**: Test Type: In vitro mammalian cell gene mutation test
Gentamicin / Betamethasone Ointment Formulation

Result: negative
Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

betamethasone:
Genotoxicity in vitro:
Test Type: Bacterial reverse mutation assay (AMES)
Result: negative
Test Type: In vitro mammalian cell gene mutation test
Result: negative
Test Type: Chromosome aberration test in vitro
Result: positive

Genotoxicity in vivo:
Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Oral
Result: equivocal

Germ cell mutagenicity- Assessment:
Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity:
Not classified based on available information.

Components:
Gentamicin:
Carcinogenicity - Assessment:
No data available

Reproductive toxicity:
May damage the unborn child.

Components:
Gentamicin:
Effects on fertility:
Test Type: Two-generation reproduction toxicity study
Species: Rat
Fertility: NOAEL: 20 mg/kg body weight
Result: No significant adverse effects were reported

Effects on foetal development:
Test Type: Embryo-foetal development
Species: Rabbit
Developmental Toxicity: NOAEL: 3.6 mg/kg body weight  
Result: No embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 75 mg/kg body weight  
Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development  
Species: Mouse  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 10 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Intraperitoneal  
Developmental Toxicity: LOAEL: 50 mg/kg body weight  
Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment: Positive evidence of adverse effects on development from human epidemiological studies.

betamethasone:  
Effects on foetal development:  
Species: Rabbit  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 0.05 mg/kg body weight  
Result: Fetotoxicity, Malformations were observed.

Species: Rat  
Application Route: Subcutaneous  
Developmental Toxicity: LOAEL: 0.42 mg/kg body weight  
Result: Malformations were observed.

Species: Mouse  
Application Route: Intramuscular  
Developmental Toxicity: LOAEL: 1 mg/kg body weight  
Result: Malformations were observed.

Reproductive toxicity - Assessment: Clear evidence of adverse effects on development, based on animal experiments.

STOT - single exposure  
Not classified based on available information.

STOT - repeated exposure  
Causes damage to organs through prolonged or repeated exposure.
Components:

Gentamicin:
Target Organs: Kidney, inner ear
Assessment: Causes damage to organs through prolonged or repeated exposure.

Betamethasone:
Target Organs: Pituitary gland, Immune system, muscle, thymus gland, Blood, Adrenal gland
Assessment: Causes damage to organs through prolonged or repeated exposure.

Repeated dose toxicity

Components:

Paraffin oil:
Species: Rat, female
LOAEL: 161 mg/kg
Application Route: Ingestion
Exposure time: 90 Days

Gentamicin:
Species: Dog
LOAEL: 3 mg/kg
Application Route: Intramuscular
Exposure time: 12 Months
Target Organs: Kidney
Symptoms: Vomiting, Salivation

Species: Monkey
LOAEL: 50 mg/kg
Application Route: Subcutaneous
Exposure time: 3 Weeks
Target Organs: Kidney, inner ear

Species: Monkey
LOAEL: 6 mg/kg
Application Route: Intramuscular
Exposure time: 3 Weeks
Target Organs: Blood, Kidney, inner ear, Liver

Species: Rat
NOAEL: 5 mg/kg
LOAEL: 10 mg/kg
Application Route: Intramuscular
Exposure time: 52 Weeks
Target Organs: Kidney, Blood

Species: Rat
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formulation

Version 4.1 Revision Date: 10.10.2020 SDS Number: 1842226-00008 Date of last issue: 23.03.2020 Date of first issue: 19.07.2017

NOAEL: 12.5 mg/kg
LOAEL: 50 mg/kg
Application Route: Intramuscular
Exposure time: 13 Weeks
Target Organs: Kidney

betamethasone:
Species: Rabbit
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 10 - 30 d
Target Organs: Pituitary gland, Immune system, muscle

Species: Rat
LOAEL: 0.05 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus gland

Species: Mouse
LOAEL: 0.1 %
Application Route: Skin contact
Exposure time: 8 Weeks
Target Organs: thymus gland

Species: Dog
LOAEL: 0.05 mg/kg
Application Route: Oral
Exposure time: 28 d
Target Organs: Blood, thymus gland, Adrenal gland

Aspiration toxicity
Not classified based on available information.

Components:

Paraffin oil:
The substance or mixture is known to cause human aspiration toxicity hazards or has to be regarded as if it causes a human aspiration toxicity hazard.

Experience with human exposure

Components:

Gentamicin:
Ingestion:
Target Organs: Kidney
Target Organs: inner ear
Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness

betamethasone:
Inhalation:
Target Organs: Adrenal gland
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formulation

Version 4.1
Revision Date: 10.10.2020
SDS Number: 1842226-00008
Date of last issue: 23.03.2020
Date of first issue: 19.07.2017

Skin contact: Symptoms: Redness, pruritis, Irritation

SECTION 12: Ecological information

12.1 Toxicity

Components:

Paraffin oil:
Toxicity to fish: LL50 (Scophthalmus maximus (turbot)): > 1.028 mg/l
Exposure time: 96 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to daphnia and other aquatic invertebrates: EL50 (Acartia tonsa): > 3.193 mg/l
Exposure time: 48 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Toxicity to algae/aquatic plants: EL50 (Skeletonema costatum (marine diatom)): > 3.200 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

NOELR (Skeletonema costatum (marine diatom)): 993 mg/l
Exposure time: 72 h
Test substance: Water Accommodated Fraction
Remarks: Based on data from similar materials

Gentamicin:
Toxicity to daphnia and other aquatic invertebrates: EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

LC50 (Americamysis): 30 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants: EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Pseudokirchneriella subcapitata (green algae)): 1,5 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

EC50 (Anabaena flos-aquae (cyanobacterium)): 4,7 µg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

NOEC (Anabaena flos-aquae (cyanobacterium)): 1,6 µg/l
Gentamicin / Betamethasone Ointment Formulation

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>SDS Number:</th>
<th>Date of last issue:</th>
<th>Date of first issue:</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10.10.2020</td>
<td>1842226-00008</td>
<td>23.03.2020</td>
<td>19.07.2017</td>
</tr>
</tbody>
</table>

**Exposure time**: 72 h
Method: OECD Test Guideline 201

**M-Factor (Acute aquatic toxicity)**: 100

**Toxicity to microorganisms**:
EC50: 288,7 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

**M-Factor (Chronic aquatic toxicity)**: 1

**betamethasone**:

**Toxicity to daphnia and other aquatic invertebrates**:
EC50 (Americamysis): > 50 mg/l
Exposure time: 96 h

**Toxicity to algae/aquatic plants**:
EC50 (Pseudokirchneriella subcapitata (green algae)): > 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

NOEC (Pseudokirchneriella subcapitata (green algae)): 34 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

**Toxicity to fish (Chronic toxicity)**:
NOEC: 0,052 mg/l
Exposure time: 32 d
Species: Pimephales promelas (fathead minnow)
Method: OECD Test Guideline 210

NOEC: 0,07 µg/l
Exposure time: 219 d
Species: Oryzias latipes (Japanese medaka)
Method: OECD Test Guideline 229

**Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)**:
NOEC: 8 mg/l
Exposure time: 21 d
Species: Daphnia magna (Water flea)
Method: OECD Test Guideline 211

**M-Factor (Chronic aquatic toxicity)**: 1.000

### 12.2 Persistence and degradability

**Components**:

**Paraffin oil**:
Biodegradability: Result: Readily biodegradable.
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formulation

Version: 4.1
Revision Date: 10.10.2020
SDS Number: 1842226-00008
Date of last issue: 23.03.2020
Date of first issue: 19.07.2017

Biodegradation: 82 %
Exposure time: 24 d
Method: OECD Test Guideline 301F
Remarks: Based on data from similar materials

Gentamicin:
Biodegradability: Result: rapidly degradable
Biodegradation: 100 %
Exposure time: 28 d
Method: OECD Test Guideline 314

12.3 Bioaccumulative potential

Components:

Gentamicin:
Partition coefficient: n-octanol/water: log Pow: < -2

betamethasone:
Partition coefficient: n-octanol/water: log Pow: 2.11

12.4 Mobility in soil
No data available

12.5 Results of PBT and vPvB assessment
Not relevant

12.6 Other adverse effects
No data available

SECTION 13: Disposal considerations

13.1 Waste treatment methods
Product: Dispose of in accordance with local regulations.
According to the European Waste Catalogue, Waste Codes are not product specific, but application specific.
Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities.

Contaminated packaging: Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.

SECTION 14: Transport information

14.1 UN number
ADN: UN 3077
ADR: UN 3077
RID : UN 3077
IMDG : UN 3077
IATA : UN 3077

14.2 UN proper shipping name
ADN : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone, Gentamicin)
ADR : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone, Gentamicin)
RID : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone, Gentamicin)
IMDG : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (betamethasone, Gentamicin)
IATA : Environmentally hazardous substance, solid, n.o.s. (betamethasone, Gentamicin)

14.3 Transport hazard class(es)
ADN : 9
ADR : 9
RID : 9
IMDG : 9
IATA : 9

14.4 Packing group
ADN
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

ADR
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9
Tunnel restriction code : (-)

RID
Packing group : III
Classification Code : M7
Hazard Identification Number : 90
Labels : 9

IMDG
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formulation

Version 4.1  Revision Date: 10.10.2020  SDS Number: 1842226-00008  Date of last issue: 23.03.2020
Date of first issue: 19.07.2017

Packing group: III
Labels: 9
EmS Code: F-A, S-F

IATA (Cargo)
Packing instruction (cargo aircraft): 956
Packing instruction (LQ): Y956
Packing group: III
Labels: Miscellaneous

IATA (Passenger)
Packing instruction (passenger aircraft): 956
Packing instruction (LQ): Y956
Packing group: III
Labels: Miscellaneous

14.5 Environmental hazards

ADN
Environmentally hazardous: yes

ADR
Environmentally hazardous: yes

RID
Environmentally hazardous: yes

IMDG
Marine pollutant: yes

IATA (Passenger)
Environmentally hazardous: yes

IATA (Cargo)
Environmentally hazardous: yes

14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

14.7 Transport in bulk according to Annex II of Marpol and the IBC Code
Remarks: Not applicable for product as supplied.

SECTION 15: Regulatory information

15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, preparations and articles (Annex XVII): Not applicable
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59): Not applicable
SAFETY DATA SHEET
according to Regulation (EC) No. 1907/2006

Gentamicin / Betamethasone Ointment Formulation

Version 4.1 Revision Date: 10.10.2020 SDS Number: 1842226-00008 Date of last issue: 23.03.2020 Date of first issue: 19.07.2017

REACH - List of substances subject to authorisation (Annex XIV): Not applicable
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer: Not applicable
Regulation (EU) 2019/1021 on persistent organic pollutants (recast): Not applicable
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import of dangerous chemicals: Not applicable

Quantity 1 Quantity 2
E1 ENVIRONMENTAL HAZARDS 100 t 200 t

Other regulations:
Take note of Directive 92/85/EEC regarding maternity protection or stricter national regulations, where applicable.
Young people under the age of 18 are not allowed to use or be exposed to the product professionally. Young people above the age of 15 are, however, except from this rule if the product is a necessary part of their education.

The components of this product are reported in the following inventories:
AICS: not determined
DSL: not determined
IECSC: not determined

15.2 Chemical safety assessment
A Chemical Safety Assessment has not been carried out.

SECTION 16: Other information
Other information: Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

Full text of H-Statements
H304: May be fatal if swallowed and enters airways.
H330: Fatal if inhaled.
H360D: May damage the unborn child.
H372: Causes damage to organs through prolonged or repeated exposure.
H372: Causes damage to organs through prolonged or repeated exposure if swallowed.
H400: Very toxic to aquatic life.
H410: Very toxic to aquatic life with long lasting effects.

Full text of other abbreviations
Acute Tox.: Acute toxicity
Aquatic Acute: Short-term (acute) aquatic hazard
# Safety Data Sheet

**According to Regulation (EC) No. 1907/2006**

**Gentamicin / Betamethasone Ointment Formulation**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date</th>
<th>SDS Number</th>
<th>Date of last issue</th>
<th>Date of first issue</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.1</td>
<td>10.10.2020</td>
<td>1842226-00008</td>
<td>23.03.2020</td>
<td>19.07.2017</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Aquatic Chronic</th>
<th>Asp. Tox.</th>
<th>Repr.</th>
<th>STOT RE</th>
<th>FOR-2011-12-06-1358</th>
<th>FOR-2011-12-06-1358 /</th>
<th>TWA</th>
</tr>
</thead>
</table>

**ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - European Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50% of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative |

**Further information**


**Classification of the mixture:**

<table>
<thead>
<tr>
<th>Repr. 1B</th>
<th>STOT RE 1</th>
<th>Aquatic Chronic 1</th>
</tr>
</thead>
<tbody>
<tr>
<td>H360D</td>
<td>H372</td>
<td>H410</td>
</tr>
</tbody>
</table>

**Classification procedure:**

Calculation method
The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user’s end product, if applicable.